Kelly Shi
Stock Analyst at Jefferies
(2.41)
# 2,493
Out of 4,960 analysts
32
Total ratings
46.67%
Success rate
1.63%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kelly Shi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Buy | $129 → $148 | $131.88 | +12.22% | 2 | Aug 13, 2025 | |
| COGT Cogent Biosciences | Maintains: Buy | $23 → $28 | $12.12 | +131.02% | 1 | Jul 7, 2025 | |
| SMMT Summit Therapeutics | Maintains: Buy | $31 → $44 | $26.20 | +67.94% | 1 | Apr 25, 2025 | |
| VSTM Verastem | Initiates: Buy | $15 | $9.08 | +65.20% | 1 | Apr 10, 2025 | |
| OPT Opthea | Downgrades: Underperform | $1 | $3.41 | -70.67% | 1 | Mar 25, 2025 | |
| TIL Instil Bio | Upgrades: Buy | $11 → $52 | $26.99 | +92.66% | 2 | Jan 7, 2025 | |
| FHTX Foghorn Therapeutics | Maintains: Buy | $18 → $14 | $5.56 | +151.80% | 2 | Dec 16, 2024 | |
| CNTA Centessa Pharmaceuticals | Maintains: Buy | $13 → $19 | $17.01 | +11.70% | 2 | Sep 11, 2024 | |
| ASND Ascendis Pharma | Maintains: Buy | $174 → $196 | $194.30 | +0.87% | 2 | Aug 13, 2024 | |
| ARTV Artiva Biotherapeutics | Initiates: Buy | $21 | $2.88 | +629.17% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $16.24 | +127.83% | 1 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $6 | $2.41 | +148.96% | 2 | Jun 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $46 | $50.57 | -9.04% | 3 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $81 | $85.04 | -4.75% | 1 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $20.11 | +74.04% | 1 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $1.62 | +2,122.22% | 1 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $55.89 | -71.37% | 1 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $44.10 | -9.30% | 1 | Aug 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $4.82 | +314.94% | 1 | Aug 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $2.31 | +246.32% | 1 | Aug 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $0.73 | +3,613.38% | 1 | Mar 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $52 | $16.11 | +222.88% | 1 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $1.83 | +1,375.41% | 1 | Apr 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $2.39 | +1,280.75% | 1 | Mar 8, 2021 |
Insmed
Aug 13, 2025
Maintains: Buy
Price Target: $129 → $148
Current: $131.88
Upside: +12.22%
Cogent Biosciences
Jul 7, 2025
Maintains: Buy
Price Target: $23 → $28
Current: $12.12
Upside: +131.02%
Summit Therapeutics
Apr 25, 2025
Maintains: Buy
Price Target: $31 → $44
Current: $26.20
Upside: +67.94%
Verastem
Apr 10, 2025
Initiates: Buy
Price Target: $15
Current: $9.08
Upside: +65.20%
Opthea
Mar 25, 2025
Downgrades: Underperform
Price Target: $1
Current: $3.41
Upside: -70.67%
Instil Bio
Jan 7, 2025
Upgrades: Buy
Price Target: $11 → $52
Current: $26.99
Upside: +92.66%
Foghorn Therapeutics
Dec 16, 2024
Maintains: Buy
Price Target: $18 → $14
Current: $5.56
Upside: +151.80%
Centessa Pharmaceuticals
Sep 11, 2024
Maintains: Buy
Price Target: $13 → $19
Current: $17.01
Upside: +11.70%
Ascendis Pharma
Aug 13, 2024
Maintains: Buy
Price Target: $174 → $196
Current: $194.30
Upside: +0.87%
Artiva Biotherapeutics
Aug 13, 2024
Initiates: Buy
Price Target: $21
Current: $2.88
Upside: +629.17%
Jun 28, 2024
Initiates: Buy
Price Target: $37
Current: $16.24
Upside: +127.83%
Jun 10, 2024
Maintains: Buy
Price Target: $15 → $6
Current: $2.41
Upside: +148.96%
May 20, 2024
Maintains: Buy
Price Target: $35 → $46
Current: $50.57
Upside: -9.04%
Feb 23, 2024
Initiates: Buy
Price Target: $81
Current: $85.04
Upside: -4.75%
Feb 20, 2024
Initiates: Buy
Price Target: $35
Current: $20.11
Upside: +74.04%
Feb 5, 2024
Initiates: Buy
Price Target: $36
Current: $1.62
Upside: +2,122.22%
Nov 11, 2022
Initiates: Buy
Price Target: $16
Current: $55.89
Upside: -71.37%
Aug 15, 2022
Initiates: Buy
Price Target: $40
Current: $44.10
Upside: -9.30%
Aug 15, 2022
Initiates: Buy
Price Target: $20
Current: $4.82
Upside: +314.94%
Aug 3, 2022
Initiates: Buy
Price Target: $8
Current: $2.31
Upside: +246.32%
Mar 4, 2022
Initiates: Buy
Price Target: $27
Current: $0.73
Upside: +3,613.38%
Aug 3, 2021
Initiates: Buy
Price Target: $52
Current: $16.11
Upside: +222.88%
Apr 13, 2021
Initiates: Buy
Price Target: $27
Current: $1.83
Upside: +1,375.41%
Mar 8, 2021
Initiates: Buy
Price Target: $33
Current: $2.39
Upside: +1,280.75%